Spyre Therapeutics has completed enrollment for all sub-studies in its SKYWAY Phase 2 trial evaluating SPY072, an anti-TL1A antibody, in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). This milestone highlights strong patient interest and the urgent need for new treatments in these conditions affecting over three million U.S. patients. Spyre expects topline data readouts for RA in Q3 2026 and for PsA and axSpA in Q4 2026. The company aims to deliver six Phase 2 trial results in 2026, potentially setting a new standard in rheumatic disease treatment with SPY072’s extended half-life and convenient dosing schedule.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
